Cancer biotech Instil Bio prices IPO at $20, the high end of the upwardly revised range

Instil Bio, an early stage biotech developing immune cell therapies for cancer, raised $320 million by offering 16 million shares at $20, the high end of the upwardly revised range of $19 to $20. The company had originally planned to offer 13.9 million shares at a range of $Read More